Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.
Q2 2013 Presentation
July 31, 2013
www.metabolix.com
@MetabolixInc
© 2013 Metabolix2
Safe Harbor Statement*
Our presentation includes, and our response to various questions may
include, for...
© 2013 Metabolix3
Growth Strategy
Key Drivers
Targeting advanced materials market through PHA technology
Building portfoli...
© 2013 Metabolix4
Q2 Progress – Samsung Collaboration
Collaboration Agreement with
Samsung Fine Chemicals
 Goal of expand...
© 2013 Metabolix5
Film/Bags: Building demand for Mvera B5008 compostable film
Performance Additives: Published white paper...
© 2013 Metabolix6
Q2 Progress – Biobased Chemicals and Crops
Biobased Chemicals
Producing renewable-based
chemicals for ap...
© 2013 Metabolix7
Q2 Progress – Intellectual Property
Biopolymers
Four patents
granted / allowed;
advanced
processing of
M...
© 2013 Metabolix8
Operations Update
Strengthening the Supply Chain
Near-term plan to utilize PHA biopolymers from 10KTPA p...
© 2013 Metabolix9
Cash Usage
In Millions
*Numbers subject to rounding.
Q2
2013
Q1
2013
Q2
2012
First Half
2013
First Half
...
© 2013 Metabolix10
Product Sales Revenue
In Millions
Q1
2012
Q2
2012
Q3
2012
Q4
2012
Q1
2013
Q2
2013
First Half
2013
First...
© 2013 Metabolix11
Financial Results
In Millions (except per share amounts)
Q2
2013
Q2
2012
First Half
2013
First Half
201...
Q2 2013 Presentation
July 31, 2013
www.metabolix.com
@MetabolixInc
Upcoming SlideShare
Loading in …5
×

Metabolix 2Q13 Earnings

1,954 views

Published on

  • Be the first to comment

  • Be the first to like this

Metabolix 2Q13 Earnings

  1. 1. Q2 2013 Presentation July 31, 2013 www.metabolix.com @MetabolixInc
  2. 2. © 2013 Metabolix2 Safe Harbor Statement* Our presentation includes, and our response to various questions may include, forward-looking statements about the Company’s future plans and objectives. Any such statements are subject to risks and uncertainties that could cause the actual results and the implementation of the Company’s plans and operations to vary materially. These risks are discussed in the Company’s filings with the S.E.C., including, without limitation, our Form 10-K filed March 28, 2013. *Under the Private Securities Litigation Reform Act of 1995
  3. 3. © 2013 Metabolix3 Growth Strategy Key Drivers Targeting advanced materials market through PHA technology Building portfolio of biopolymer products: film, performance additives and functional biodegradation segments Developing customer relationships in advance of commercial production Working to establish a robust supply chain based on 10KTPA of PHA capacity Producing highly differentiated biobased chemicals and a biorefinery system with crops through proprietary PHA technology Creating commercial opportunities and competitive barriers through extensive IP position
  4. 4. © 2013 Metabolix4 Q2 Progress – Samsung Collaboration Collaboration Agreement with Samsung Fine Chemicals  Goal of expanding the global market for biodegradable polymers  Products designed to deliver best performance and value to targeted customer applications  All products developed will complement the product portfolios of each company  Extension of work that commenced in early 2012 Samsung MBLX Products PBAT PBS Wide Range of PHAs Region Asia Australia New Zealand N.A. E.U.
  5. 5. © 2013 Metabolix5 Film/Bags: Building demand for Mvera B5008 compostable film Performance Additives: Published white paper in Plastics Technology, expanding data set and developing customer relationships in PVC Functional Biodegradation: Delivering tailored solutions into water treatment applications and developing latex product with partners Q2 Progress – Biopolymers Biopolymers
  6. 6. © 2013 Metabolix6 Q2 Progress – Biobased Chemicals and Crops Biobased Chemicals Producing renewable-based chemicals for applications that typically relied on fossil fuels Achieving our technical and commercial milestones in C4 and C3 Increasing interest in C3 (bioacrylic) technology Acrylic consumers demanding biocontent Crops Working on several grants Research targets multi-gene expression and plant transformation MIT Technology Review published article highlighting our process for making PHB in switchgrass Article available on our website
  7. 7. © 2013 Metabolix7 Q2 Progress – Intellectual Property Biopolymers Four patents granted / allowed; advanced processing of Mirel biopolymer resin to enhance performance attributes Crops Granted a U.S. patent covering production of PHB in switchgrass Granted / Allowed Six Patents in Q2 Patent allowed as first in a family covering engineered systems to produce biomass to convert into C5 chemicals
  8. 8. © 2013 Metabolix8 Operations Update Strengthening the Supply Chain Near-term plan to utilize PHA biopolymers from 10KTPA plant Focused clearly on 3 sites for commercial manufacturing of PHA  Restructuring of Antibióticos underway with prior management removed and new ownership emerging  Actively evaluating two sites for U.S.-based manufacturing facility Product and market development  Potential for approximately $100MM revenue stream  Combining performance PHAs with PBAT, PBS, PLA and starches for high-value applications
  9. 9. © 2013 Metabolix9 Cash Usage In Millions *Numbers subject to rounding. Q2 2013 Q1 2013 Q2 2012 First Half 2013 First Half 2012 Cash Used in Operating Activities $5.8 $ 8.5 $5.9 $14.3 $18.1 One-Time Uses • Inventory Purchase $0.0 $ 0.0 $0.0 $0.0 $3.0 • Restructuring Expenses $0.0 $ 0.0 $0.0 $0.0 $0.9 Normalized Cash Usage (adjusted for one-time uses) $5.8 $ 8.5 $5.9 $14.3 $14.2 Other Cash Usage $0.2 $0.1 $0.2 $0.3 $0.4 Ending Cash & Investment Balance $31.7 $ 37.7 $59.9 $31.7 $59.9
  10. 10. © 2013 Metabolix10 Product Sales Revenue In Millions Q1 2012 Q2 2012 Q3 2012 Q4 2012 Q1 2013 Q2 2013 First Half 2013 First Half 2012 Orders Shipped and billed $0.0 $0.4 $0.7 $0.9 $0.7 $0.4 $1.1 $0.4 Deferred at period end1 0.0 0.0 (0.6) (0.8) (0.7) (0.3) (0.3) 0.0 Current quarter shipments recognized $0.0 $0.4 $0.1 $0.1 $0.0 $0.1 $0.8 $0.4 Deferred orders recognized 0.0 0.0 0.0 0.6 0.8 0.7 0.8 0.0 Total Product Revenue Recognized $0.0 $0.4 $0.1 $0.7 $0.8 $0.8 $1.6 $0.4 1 The Company’s product revenue recognition policy is to defer recognition of product revenue until the later of sixty days or receipt of customer payment. *Numbers subject to rounding.
  11. 11. © 2013 Metabolix11 Financial Results In Millions (except per share amounts) Q2 2013 Q2 2012 First Half 2013 First Half 2012 Revenue $1.7 $0.9 $3.6 $40.2 Cost of Product Revenues $1.2 $0.4 $1.8 $0.5 R&D Expense $4.9 $5.0 $9.8 $11.1 SG&A Expense $3.4 $3.4 $6.7 $7.8 Net Income (Loss) Per share ($7.9) ($0.23) ($7.9) ($0.23) ($14.6) ($0.43) $20.9 $0.61 *Numbers subject to rounding.
  12. 12. Q2 2013 Presentation July 31, 2013 www.metabolix.com @MetabolixInc

×